Pazopanib has been shown to be clinically effective in metastatic urothelial cancer, according to the final results of a study conducted by Andrea Necchi and colleagues. In the phase II trial, 41 patients with refractory disease who had been previously treated with chemotherapy received 800 mg once-daily pazopanib. At follow-up, 17% had a partial response to therapy and 59% patients had stable disease, which translates into 76% of patients benefiting from the drug. Median progression-free survival and overall survival were 2.6 months and 4.7 months, respectively. More importantly, interleukin-8 was identified as clear indicator of tumour progression and shorter overall survival after just 4 weeks of treatment.